Skip to content

Author

G. Abou-Alfa

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · 0 citations
Review Sep 2026

Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90Y Radioembolization with Immunotherapy in HCC.

Combination approaches using systemic immunotherapy agents are now standard of care for patients with advanced-stage hepatocellular carcinoma (HCC), resulting in improved overall survival. However, even with optimal systemic regimens, fewer than 40% of cases respond to treatment, presumably due to resistance mechanisms...

R. Avritscher, Edward Kim, Valerie Chew et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.